<qa>  What is the LDL-C level at Visit 3?The duration of the study for each subject will be approximately 7 weeks. Each subject will be scheduled for 3-4 study visits. Visits 1 and 2 are screening visits; these visits may be combined. At Visit 3, those subjects who meet the enrollment criteria will be randomized to one of two treatment groups: ezetimibe 10 mg or ezetimibe placebo to be taken with ongoing open-label atorvastatin 10 mgday. Randomization will be stratified based on the LDL-C level at Visit 3: 3.3 mmolL 130 mgdL or 3.3 mmolL 130 mgdL. Subjects will be treated for 6 weeks and then return for a final visit, Visit 4. 